VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE AMEX: CVM), a late stage cancer company, announced today that Geert Kersten, Chief Executive Officer, will be presenting an overview of the upcoming Phase III clinical trial with the Company’s cancer immunotherapy product Multikine® at the Rodman & Renshaw Annual Global Healthcare Conference. The conference will take place May 16-18 at the Grosvenor House Hotel in London, UK.
Mr. Kersten’s presentation will be on Monday, May 17th, at 11:30 a.m. London time. The presentation will be webcast live with slides and archived for 90 days. The webcast will be available on the Company’s website at www.cel-sci.com.
About CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using its L.E.A.P.S.TM technology platform. The LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. This investigational treatment is currently being tested in a clinical study at Johns Hopkins University. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
Gavin de Windt, 703-506-9460
KEYWORDS: United Kingdom United States Europe North America Virginia
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Infectious Diseases Oncology Pharmaceutical